|
TABATA Tsutomu
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Position Professor and Division head |
|
| Article types | Original article |
| Language | English |
| Peer review | Peer reviewed |
| Title | Prognostic Benefit of ≥6 Cycles of Neoadjuvant Chemotherapy for Advanced Ovarian, Tubal, and Peritoneal Cancers. |
| Journal | Formal name：Anticancer research Abbreviation：Anticancer Res ISSN code：17917530/02507005 |
| Domestic / Foregin | Foregin |
| Volume, Issue, Page | 41(8),pp.4157-4161 |
| Author and coauthor | Kondo Eiji, Nimura Ryo, Maki Shintaro, Kaneda Michiko, Nii Masafumi, Yoshida Kenta, Tabata Tsutomu, Ikeda Tomoaki |
| Publication date | 2021/08 |
| Summary | BACKGROUND/AIM:A higher number of neoadjuvant chemotherapy (NACT) cycles translate to a lower risk of morbidity and mortality, but few studies have analyzed the prognostic impact of >4 cycles of NACT.PATIENTS AND METHODS:Overall, 52 patients [31 patients, NACT plus interval debulking surgery (IDS); 21 patients, NACT alone owing to progressive disease] who underwent NACT between January 2008 and December 2014 were evaluated.RESULTS:In total, 6, 7-10, and 11-18 cycles of NACT were performed in 52.3%, 27.3%, and 20.5% of the patients, respectively. The median overall survival was 76.0 months (range=36.0-94.0 months), and the median progression-free survival was 26.0 months (range=18.0-54.0 months) in the NACT plus IDS group.CONCLUSION:At least six cycles of NACT plus IDS are associated with a lower rate of multi-organ resection and a high rate of complete resection or optimal (<1 cm) following IDS. |
| DOI | 10.21873/anticanres.15219 |
| PMID | 34281887 |